Our Q2 2025 results will be published on August 7, 2025, at 7 a.m. (CEST). Our conference call for the media will take place at 10:00 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST).
Investors
Welcome to our Investor Relations
Here you’ll find everything you might be interested in if you want to invest in vibrant science and technology.
-
![investors-compass-cutout]()
5 reasons to invest
We develop products and solutions that make life better – and have been successfully doing so for more than 350 years. And when you’ve prospered for centuries as we have, you must have done a few things right.Read More -
![Sustainable Development Goals 800 600 4 3]()
Sustainability
For us, scientific progress and responsible entrepreneurship go hand in hand, enabling us to create a sustainable future for everyoneRead more -
![Generic Graphic]()
Reports & Financials
Merck KGaA, Darmstadt, Germany, keeps growing profitably. The excellent performance of our business shows that we are on the right track. See for yourself in our comprehensive reports and financials.Read More
Upcoming Events
View All EventsOur Q3 2025 results will be published on November 13, 2025, at 7 a.m. (CET). Our conference call for the media will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Investor Related News
View All News-
Press Releases
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in SLE at EULAR ...
Company presents phase 2 data of enpatoran in systemic lupus erythematosus, highlighting improved efficacy in patients with active skin manifestations
2025/06/12
-
Press Releases
China’s Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany’s ...
The Center for Drug Evaluation of the China National Medical Products Administration officially accepted the application for pimicotinib for TGCT.
2025/06/10
-
Press Releases
Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy ...
Merck KGaA, Darmstadt, Germany, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER trial evaluating pimicotinib in TGCT.
2025/05/28
Share Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Check Share Price
Capital Market Days
Learn MoreCapital Market Days
At our Capital Market Days, our shareholders have the opportunity to meet our management and gain insights into our success story. We inform investors about our strategy, the latest financial developments and about our plans for the future.
Webcasts & Presentations
Learn MoreWebcasts & Presentations
There is a large number of presentations and webcasts of different events available for download. They provide helpful insights into our company, our businesses and executives as well as our financial development.
Annual General Meeting
Learn MoreAnnual General Meeting
Every year, our shareholders come together to make important decisions on our company’s business. We provide comprehensive material to help them make well-informed voting decisions.
Get in touch!
We're here to help. Get in touch if you have any questions.
+49 6151 72 3321
+49 6151 72 91 3321